Differentially Expressed Genes Between Mild and Severe
Patients with Class II Mutation
DAmong 29 differentially expressed genes (Table S1), Tumor
Necrosis Factor Receptor Superfamily, Member 11A (TNFRSF11A; RANK,
p=0.01), Potassium Voltage-Gated Channel (KCNE1, p=0.02),Syntaxin 1A (STX1A, p=0.008) and Solute Carrier Family 9
Member 3 Regulator 2 (SLC9A3R2; NHERF-2, p=0.03) demonstrated
significant upregulation in severe (F1-P2 and F2-P2) compared to mild
(F1-P1 and F2-P1) patients. On the other hand, Chemokine (CXC
motif) Ligand 1 (CXCL1, p=0.02), CFTR (p=0.04) and Chemokine (CXC
motif) Ligand 2 (CXCL2, p=0.03) demonstrated significant decreased
expression in severe patients (Figure 1).